Related Experiment Video
Updated: Nov 25, 2025
Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
Published on: February 27, 2016
Cellular molecular and proteomic profiling deciphers the SIRT1 controlled cell death pathways in esophageal
Huige Jiang1, Ketki Patil1, Aksal Vashi1
1Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.
Abstract:
Worldwide prevalence of esophageal adenocarcinomas with high rates of mortality coupled with increased mutations in esophageal cells warrants investigation to understand deregulation of cell signaling pathways leading to cancer. To this end, the current study was undertaken to unravel the cell death signatures using the model human esophageal adenocarcinoma cell line-OE33. The strategy involved targeting the key epigenetic modulator SIRT1, a histone deacetylase by a small molecule inhibitor - sirtinol. Sirtinol induced a dose-dependent inhibition of cell viability under both normoxic and hypoxic conditions with long term impact on proliferation as shown by clonogenic assays. Signature apoptotic signaling pathways including caspase activation and decreased Bcl-2 were observed. Proteomic analysis highlighted an array of entities affected including molecules involved in replication, transcription, protein synthesis, cell division control, stress-related proteins, spliceosome components, protein processing and cell detoxification/degradation systems. Importantly, the stoichiometry of the fold changes of the affected proteins per se could govern the cell death phenotype by sirtinol. Sirtinol could also potentially curb resistant and recurrent tumors that reside in hypoxic environments. Overall, in addition to unraveling the cellular, molecular and proteomics basis of SIRT1 inhibition, the findings open up avenues for designing novel strategies against esophageal adenocarcinoma.
Insights
Sirtinol, a SIRT1 inhibitor, effectively reduces esophageal cancer cell viability and proliferation. This study reveals its impact on apoptosis and proteomic pathways, offering potential for treating resistant tumors.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Esophageal adenocarcinoma has high mortality rates and increasing prevalence.
- Understanding cancer cell signaling deregulation is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the cell death signatures induced by targeting SIRT1 (a histone deacetylase) using the inhibitor sirtinol in OE33 esophageal adenocarcinoma cells.
- To unravel the cellular, molecular, and proteomics basis of SIRT1 inhibition.
Main Methods:
- Utilized the OE33 human esophageal adenocarcinoma cell line.
- Administered the small molecule inhibitor sirtinol targeting SIRT1.
- Performed cell viability assays (normoxic and hypoxic), clonogenic assays, and proteomic analysis.
Main Results:
- Sirtinol demonstrated dose-dependent inhibition of cell viability and proliferation.
- Induced apoptosis via caspase activation and decreased Bcl-2 expression.
- Proteomic analysis revealed widespread effects on cellular processes including replication, transcription, and protein synthesis.
Conclusions:
- Sirtinol effectively inhibits SIRT1, leading to cell death and impacting multiple cellular pathways in esophageal adenocarcinoma.
- Findings suggest sirtinol's potential in combating resistant and recurrent tumors, particularly in hypoxic environments.
- Opens new avenues for therapeutic strategies against esophageal adenocarcinoma.
